<DOC>
	<DOCNO>NCT01253629</DOCNO>
	<brief_summary>This Phase IIb study design ass whether 3 dos AFQ056 safe effective treat behavioral symptom Fragile X Syndrome .</brief_summary>
	<brief_title>Safety Efficacy AFQ056 Adult Patients With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Patients Fragile X Syndrome , least moderately ill base Clinical Global Impression Severity score least 4 qualify score ABCC IQ test Visit 1 Advanced , severe unstable disease may interfere study outcome evaluation Cancer within past 5 year , localize skin cancer Current treatment two psychoactive medication , exclude antiepileptic History severe selfinjurious behavior Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Fragile X Syndrome</keyword>
	<keyword>Martin-Bell Syndrome</keyword>
	<keyword>Genetic Diseases</keyword>
	<keyword>X-Linked</keyword>
</DOC>